| Name | Title | Contact Details |
|---|
Physio-Control, now part of Stryker, is the world leader in the development, manufacture, sale and service of external defibrillator/monitors and emergency medical response products and services. We envision a world in which no person dies suddenly as a result of an acute, treatable medical event. Physio-Control Team Members are part of a unique group who love what they do - and why they do it. Our Team is comprised of talented individuals who have purpose, creativity and passion, and we are proud to be leading the industry dedicated to saving and extending lives around the globe. Our Team Members are our most valuable asset and what sets us apart from our competitors. We are committed to our mission to save lives through hard work and dedication.
MedTec is a Hillsborough, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vbm Medical Inc is a Noblesville, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cutera was established in the San Francisco Bay Area (Brisbane) in 1998 by veteran laser and optical engineers. As the pioneer of Nd:YAG technology, CUTERA® is the trusted authority in Face + Body energy-based medical aesthetic technologies that practitioners around-the-world turn to for innovation, sophistication and performance. At Cutera, we`re always looking forward; developing new solutions, products and industry-leading services designed around the needs of medical aesthetic community—delivering better results, faster and safer than ever before. CUTERA`s premium portfolio of products include: xeo®, truSculpt® and excel V™. In 2014, CUTERA introduced two new exciting additions to their family of premium products: excel HR™ for high-speed, comfortable, hair removal and enlighten™, the industry`s first Picosecond + Nanosecond + 2 Wavelength High-Powered laser system. Today, our worldwide presence is represented in 40 countries, with direct operations in North America, France, Australia, Belgium, the Netherlands and Luxembourg.
JenaValve Technology, Inc., based in Irvine, California and Munich, Germany develops, manufactures and markets transcatheter aortic valve implantation (TAVI) systems to treat patients suffering from aortic valve disease. The Company’s transapical TAVI system is CE marked and currently marketed in Europe and other markets worldwide and its new transfemoral TAVI system is currently undergoing clinical evaluation in Europe with a view toward achieving CE Mark in 2015. JenaValve is backed by world-class U.S., European and Asian investors, including Atlas Venture, Edmond de Rothschild Investment Partners, GIMV, NeoMed Management, Legend Capital, VI Partners, Sunstone Capital, Omega Funds, Biovest and Valiance Advisors.